Introduction: Industry payments to physicians may influence prescribing patterns. Prior studies have focused on comparing more efficacious, newer brand-name medications to older generics, which could introduce confounding. Evaluating the influence of industry payments on prescribing patterns between brand-named TNF-a inhibitors represents an opportunity to reduce potential confounding by examining similar medications in the same therapeutic class, with similar clinical indications. Methods: Cross-sectional analysis of Medicare Part D prescribing data for etanercept and adalimumab in 2015 and Open Payments data from the associated manufacturers in 2014 and 2015. The association between square root transformed payments from associated manufacturers and the ratio of prescribing etanercept to adalimumab was assessed with linear regression, controlling for specialty, gender, and years in practice. Secondary analyses included evaluating the association between the number of payments and prescribing practices as well as comparing food & beverage payments to other payment types. Results: Increased total payments from the etanercept manufacturer, Amgen, Inc, were associated with an increased ratio of prescribing etanercept to adalimumab (0.010, 95% CI 0.004 to 0.016); conversely, increased total payments from the adalimumab manufacturer, AbbVie, Inc, were associated with a decreased ratio of prescribing (-0.013, 95% CI -0.017 to -0.069). An increased number of payments from AbbVie, Inc relative to Amgen, Inc was associated with a decreased ratio of prescribing etanercept to adalimumab (-0.015, 95% CI -0.020 to -0.009). Conclusions: Industry payments are associated with increased prescribing even among similar brand medications in the same therapeutic class. Both an increased number of interactions and increased total payments were assocaited with increased prescribing.
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Chronic exposure to statin drugs and association with melanoma: A report from the RADAR (Research on Adverse Drug Events and Reports) project V Singam, KA Orrell, KR Patel, S Rastogi, RC Kelm, SM Rangel, AE Laumann, DP West and B Nardone Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL There are reports of melanoma (MM) after chronic exposure to a statin and 26% of the US population aged 40 and older are now estimated by the CDC to be chronically exposed to a statin, yet no statin describes MM as a risk in the Full Prescribing Information. We searched (01/01/2001 to 10/31/2017) a large Midwestern U.S. patient population, the Northwestern Medicine Electronic Data Warehouse, comprising a medical record data repository (> 5 million patients) that yielded data from adults (18-89 years) with at least 5 years of in-clinic follow-up. The statin-exposed population consisted of all patients exposed to atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin for 12 consecutive months, while the control population consisted of non-statin-exposed patients within the same database. The outcome was MM occurring 12 months after first exposure (exposed index-date) or first in-clinic date (non-exposed index-date). Data for patients with prior history of MM or statin exposure before the index date were excluded. Adjusted odds ratios (aORs) were obtained by multivariate logistic regression analysis. Data for 454,201 patients met inclusion criteria, and 56,089 were statin-exposed, of whom 661 (1.2%) were subsequently diagnosed with MM, yielding a significant association (aOR: 1.11; 95%CI 1.02-1.22; p ¼ 0.02). Importantly, data for the age group (40-75 years) subject to recommendations from the US Preventive Services Task Force, showed a highly significant association (aOR: 1.19; 95%CI 1.08-1.31; p ¼ 0.0003). Findings in this patient population show a significant association between chronic statin exposure and subsequent incident MM that points to the need for enhanced surveillance strategies, especially for those with preexisting risk factors for MM.
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Vitiligo is associated with multiple mental health disorders and psychiatric emergencies in the United States KR Patel 1 , V Singam 1 , S Rastogi 1 , H Lee 1 and JI Silverberg 2 1 Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL and 2 Northwestern University Feinberg School of Medicine, Chicago, IL Vitiligo is a chronic auto-inflammatory skin disorder that is associated with decreased selfesteem and quality of life, which may negatively impact mental health. However, little is known about the comorbid mental health disorders and/or emergencies associated with vitiligo. We sought to determine the association between vitiligo and mental health emergencies. We analyzed data from the National Inpatient Sample, including a representative sample of w20% of hospitalizations between 2002-2012 in the US (n¼87,053,155). Overall, there were 11,573 child or adult hospital admissions with a diagnosis of vitiligo (45.13% female; 44.75% Caucasian). In multivariable logistic regression models controlling for age, sex, race/ethnicity, and insurance type, vitiligo was statistically significantly associated with 14 of 15 psychiatric disorders investigated. Specifically, vitiligo was associated with anxiety (adjusted odds ratio [95% confidence interval]: Little is known about the impact of sleep disturbances (SD) or sleep-related impairment (SRI) in adults with AD, or their relationship with severity of AD, itch and other predictors. We conducted a prospective online questionnaire-based study of 287 adults with AD, including assessment of AD severity by patient-oriented eczema measure (POEM), self-reported global AD severity, self-assessed eczema area and severity index (SA-EASI) and visual analog scale (VAS-) itch, and Patient Reported Outcome Measurement Information System (PROMIS) SD and SRI individual items and T scores. Adults with AD commonly endorsed at least some impact from all SD and SRI symptoms examined; only 58 (21.8%) reported having good or very good sleep quality in the past week. However, only a minority of adults with AD endorsed more profound impact from these individual aspects of SD and SRI in the past week or had PROMIS T scores >55. In particular, SD and SRI were associated with severe or very severe AD (POEM, self-reported severity, VAS-itch and/or SA-EASI). SRI were also associated with comorbid hay fever and/or anxiety. This study suggests that SD and SRI are common in adults with AD, particularly those with severe disease. SD and SRI should be considered when assessing burden of AD and making therapeutic decisions.
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Adult-onset generalized morphea: A retrospective review of 75 patients HB Castillo Valladares and SM Ramachandran Department of Dermatology, Yale School of Medicine, New Haven, CT Morphea is a rare fibrosing disorder marked by collagen deposits in the dermis, causing functional and cosmetic impairment, disability, and poor quality of life. The purpose of our study was to review a large cohort of patients with generalized morphea (GM) and describe their demographic and clinical characteristics. A total of 115 charts were reviewed of patients seen at our clinics in the last 5 years; 75 patients with GM were identified, excluding patients with radiation-induced morphea and scleroderma. There was a female predominance with 85.3% female patients (n ¼ 64) and 14.7% (n ¼ 11) male patients. The racial and ethnic distribution was 76% white, 10.6% Hispanic, 5.3% African American, 2.6% Asian, and 5.3% other (Pacific Islander, Native American, etc). The mean age was 39.6 years (SD ¼ 14.6). The mean interval between GM onset and diagnosis was 28.7 months. The trunk (n ¼ 30) and extremities (n ¼ 22) were the most common sites for lesions; the neck and face accounted for a minority of lesions (n ¼ 16). Extracutaneous manifestations included arthralgias (n ¼ 11), synovitis (n ¼ 9), contractures (n ¼ 6), carpal tunnel syndrome (n ¼ 4), Raynaud phenomenon (n ¼ 3) and uveitis (n ¼ 1). Concomitant autoimmune conditions included vitiligo (n ¼ 3), systemic lupus erythematosus (n ¼ 2), Sjö gren's syndrome (n ¼ 2), Hashimoto's thyroiditis (n ¼ 1), and alopecia areata (n ¼ 1). Antinuclear antibodies (ANA) were tested in 52% (39 of 75) of patients and were positive (titer 1:160) in 41% (16 of 39) of those tested. Treatment regimens included methotrexate, ultraviolet B phototherapy, calcitriol, doxycycline, and topical agents, amongst others. Conclusion: This study represents one of the largest adultonset GM cohorts to date. In our study, adult-onset GM was associated with extracutaneous sequelae and autoimmune conditions with positive ANA rate of 41%. This rate is comparable with previous studies and may represent a characteristic antigenic pattern for this morphea subtype. Future investigation is needed to further characterize adult-onset GM.
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